{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:35:26Z","timestamp":1761863726186},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T00:00:00Z","timestamp":1490659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bjc.2017.83","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T20:02:41Z","timestamp":1490731361000},"page":"1287-1293","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study"],"prefix":"10.1038","volume":"116","author":[{"given":"David L","family":"Phelps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane V","family":"Borley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty J","family":"Flower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Dina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Darb-Esfahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte S","family":"Wilhelm-Benartzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanta","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacey","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harun","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina-Therese","family":"Likos-Corbett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Ghaem-Maghami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,28]]},"reference":[{"issue":"7","key":"BFbjc201783_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3 (7): 502\u2013516.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"BFbjc201783_CR2","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.4049\/jimmunol.180.8.5653","volume":"180","author":"R Al-Sadi","year":"2008","unstructured":"Al-Sadi R, Ye D, Dokladny K, Ma TY (2008) Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 180 (8): 5653\u20135661.","journal-title":"J Immunol"},{"issue":"224","key":"BFbjc201783_CR3","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih LM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr . (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6 (224): 224ra24.","journal-title":"Sci Transl Med"},{"issue":"7","key":"BFbjc201783_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/bjc.2012.376","volume":"107","author":"J Borley","year":"2012","unstructured":"Borley J, Wilhelm-Benartzi C, Brown R, Ghaem-Maghami S (2012) Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. Br J Cancer 107 (7): 1069\u20131074.","journal-title":"Br J Cancer"},{"issue":"5","key":"BFbjc201783_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/CIRCRESAHA.107.161687","volume":"102","author":"JY Chan","year":"2008","unstructured":"Chan JY, Takeda M, Briggs LE, Graham ML, Lu JT, Horikoshi N, Weinberg EO, Aoki H, Sato N, Chien KR, Kasahara H (2008) Identification of cardiac-specific myosin light chain kinase. Circ Res 102 (5): 571\u2013580.","journal-title":"Circ Res"},{"issue":"3","key":"BFbjc201783_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1155\/2012\/473251","volume":"32","author":"L Chen","year":"2012","unstructured":"Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z, Liu B (2012) Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis markers 32 (3): 195\u2013202.","journal-title":"Dis markers"},{"issue":"1","key":"BFbjc201783_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","volume":"114","author":"DS Chi","year":"2009","unstructured":"Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114 (1): 26\u201331.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"BFbjc201783_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-014-0036-2","volume":"7","author":"JL Chou","year":"2015","unstructured":"Chou JL, Huang RL, Shay J, Chen LY, Lin SJ, Yan PS, Chao WT, Lai YH, Lai YL, Chao TK, Lee CI, Tai CK, Wu SF, Nephew KP, Huang TH, Lai HC, Chan MW (2015) Hypermethylation of the TGF-beta target, ABCA1 is associated with poor prognosis in ovarian cancer patients. Clin Epigenetics 7 (1): 1.","journal-title":"Clin Epigenetics"},{"issue":"Pt 11","key":"BFbjc201783_CR9","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1242\/jcs.02926","volume":"119","author":"LE Connell","year":"2006","unstructured":"Connell LE, Helfman DM (2006) Myosin light chain kinase plays a role in the regulation of epithelial cell survival. J Cell Sci 119 (Pt 11): 2269\u20132281.","journal-title":"J Cell Sci"},{"issue":"12","key":"BFbjc201783_CR10","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1158\/1078-0432.CCR-10-3021","volume":"17","author":"W Dai","year":"2011","unstructured":"Dai W, Teodoridis JM, Zeller C, Graham J, Hersey J, Flanagan JM, Stronach E, Millan DW, Siddiqui N, Paul J, Brown R (2011) Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 17 (12): 4052\u20134062.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"BFbjc201783_CR11","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1158\/1078-0432.CCR-13-1217","volume":"19","author":"W Dai","year":"2013","unstructured":"Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R (2013) Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin Cancer Res 19 (20): 5788\u20135797.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"BFbjc201783_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ijc.23563","volume":"123","author":"H Fiegl","year":"2008","unstructured":"Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M (2008) HOXA11 DNA methylation\u2014a novel prognostic biomarker in ovarian cancer. Int J Cancer 123 (3): 725\u2013729.","journal-title":"Int J Cancer"},{"issue":"11","key":"BFbjc201783_CR13","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/annonc\/mdt370","volume":"24","author":"JM Flanagan","year":"2013","unstructured":"Flanagan JM, Wilhelm-Benartzi CS, Metcalf M, Kaye SB, Brown R (2013) Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. Ann Oncol 24 (11): 2813\u20132818.","journal-title":"Ann Oncol"},{"issue":"5","key":"BFbjc201783_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djv369","volume":"108","author":"SK Gupta","year":"2015","unstructured":"Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN (2015) Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst 108 (5): 1\u201310.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"BFbjc201783_CR15","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1096\/fj.10-177808","volume":"25","author":"YJ Han","year":"2011","unstructured":"Han YJ, Ma SF, Yourek G, Park YD, Garcia JG (2011) A transcribed pseudogene of MYLK promotes cell proliferation. FASEB J 25 (7): 2305\u20132312.","journal-title":"FASEB J"},{"issue":"10","key":"BFbjc201783_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (10): 997\u20131003.","journal-title":"N Engl J Med"},{"issue":"0","key":"BFbjc201783_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cca.2013.07.023","volume":"425","author":"B Keeley","year":"2013","unstructured":"Keeley B, Stark A, Pisanic Ii TR, Kwak R, Zhang Y, Wrangle J, Baylin S, Herman J, Ahuja N, Brock MV, Wang T-H (2013) Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. Clin Chim Acta 425 (0): 169\u2013175.","journal-title":"Clin Chim Acta"},{"key":"BFbjc201783_CR18","unstructured":"Laboratories K (2013) Kyoto Encyclopedia of Genes and Genomes Vol. 2013. Available from: \n                    http:\/\/www.genome.jp\/kegg\/\n                    \n                   (accessed on 2013)."},{"issue":"9","key":"BFbjc201783_CR19","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstrom","year":"2012","unstructured":"Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13 (9): 916\u2013926.","journal-title":"Lancet Oncol"},{"key":"BFbjc201783_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1471-2164-15-119","volume":"15","author":"YA Medvedeva","year":"2014","unstructured":"Medvedeva YA, Khamis AM, Kulakovskiy IV, Ba-Alawi W, Bhuyan MS, Kawaji H, Lassmann T, Harbers M, Forrest AR, Bajic VB (2014) Effects of cytosine methylation on transcription factor binding sites. BMC Genomics 15: 119.","journal-title":"BMC Genomics"},{"key":"BFbjc201783_CR21","unstructured":"NICE (2011) The recognition and initial management of ovarian cancer, Clinical guideline 122: NICE. Available from: \n                    http:\/\/nice.org.uk\/Guidance\/cg122\n                    \n                  ."},{"issue":"7","key":"BFbjc201783_CR22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1471-0528.2008.01692.x","volume":"115","author":"C Pomel","year":"2008","unstructured":"Pomel C, Barton DP, McNeish I, Shepherd J (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG 115 (7): 808\u2013810.","journal-title":"BJOG"},{"issue":"2","key":"BFbjc201783_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","volume":"20","author":"R Sankaranarayanan","year":"2006","unstructured":"Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20 (2): 207\u2013225.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"2","key":"BFbjc201783_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3802\/jgo.2010.21.2.75","volume":"21","author":"KK Shih","year":"2010","unstructured":"Shih KK, Chi DS (2010) Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol 21 (2): 75\u201380.","journal-title":"J Gynecol Oncol"},{"issue":"7353","key":"BFbjc201783_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"TCGARN","year":"2011","unstructured":"TCGARN (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474 (7353): 609\u2013615.","journal-title":"Nature"},{"issue":"16","key":"BFbjc201783_CR26","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14 (16): 5198\u20135208.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"BFbjc201783_CR27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363 (10): 943\u2013953.","journal-title":"N Engl J Med"},{"issue":"11","key":"BFbjc201783_CR28","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1158\/0008-5472.CAN-13-3198","volume":"74","author":"C Wang","year":"2014","unstructured":"Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL (2014) Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Res 74 (11): 3084\u20133091.","journal-title":"Cancer Res"},{"issue":"6","key":"BFbjc201783_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1245\/s10434-010-0964-9","volume":"17","author":"P Wimberger","year":"2010","unstructured":"Wimberger P (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease. Ann Surg Oncol 17 (6): 1642\u20131648.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"BFbjc201783_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ygyno.2012.11.002","volume":"128","author":"L Yu","year":"2013","unstructured":"Yu L, Deng L, Li J, Zhang Y, Hu L (2013) The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 128 (2): 391\u2013396.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"BFbjc201783_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/IGC.0b013e3182788466","volume":"23","author":"D Zhao","year":"2013","unstructured":"Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23 (1): 25\u201333.","journal-title":"Int J Gynecol Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201783","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.83","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201783.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:41:49Z","timestamp":1684417309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,28]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbjc201783"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.83","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,28]]},"assertion":[{"value":"21 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IB has honoraria from Fujirebio, Myriad Genetics, Roche, Glycotype GmbH, and AstraZeneca, and consulting or advisory roles with Glycotype and Fujirebio. She has received research funding from Takeda, Angle, and AstraZeneca, and travel, accommodation, or expenses payments from GlaxoSmithKline, Amgen, Essex Pharma, Fujirebio, and Roche. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}